U.S. Markets closed

ImmunoGen, Inc. (IMGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7125-0.36 (-7.05%)
At close: 4:00PM EDT
People also watch
SGENIMMUEXELINCYCLDX
Interactive chart
Previous Close5.0700
Open5.0500
Bid4.3000 x 2000
Ask5.0000 x 1000
Day's Range4.5550 - 5.0550
52 Week Range1.5100 - 6.2100
Volume2,317,040
Avg. Volume2,459,421
Market Cap421.05M
Beta2.64
PE Ratio (TTM)-2.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher
    Zacks8 days ago

    ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher

    ImmunoGen, Inc. (IMGN) shares jumped above 14% in the last trading session.

  • Why ImmunoGen, Inc. Jumped Higher Today
    Motley Fool9 days ago

    Why ImmunoGen, Inc. Jumped Higher Today

    Data to be presented at ASCO looks strong.

  • Reuters10 days ago

    ImmunoGen drug moving ahead in single-agent, combination trials

    Latest results from a mid-stage trial of ImmunoGen Inc's experimental antibody-drug conjugate show that it shrinks or stabilizes tumors in nearly half of advanced ovarian cancer patients with at least medium levels of a key biomarker whose disease has become resistant to standard chemotherapy. For its pivotal trial, ImmunoGen is enrolling only patients with platinum-resistant disease and medium or high levels of a biomarker known as folate receptor alpha who have received up to three prior lines of therapy. "We are looking to get on the market as quickly as possible in the single agent setting," ImmunoGen Chief Executive Mark Enyedy told Reuters.